We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Utibron Neohaler (indacaterol and glycopyrrolate)

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Utibron Neohaler (indacaterol and glycopyrrolate)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Utibron Neohaler is a fixed dose combination of glycopyrronium bromide, a once-daily long-acting muscarinic antagonist, and indacaterol, a once-daily long-acting beta-2 agonist.

    Utibron Neohaler is specifically indicated for the long term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

    Utibron Neohaler is supplied as an inhalation powder, for oral inhalation use. The recommended dose is the inhalation of the contents of one Utibron capsule twice daily using the Neohaler device. Utibron Neohaler should be administered at the same time of the day, (1 capsule in the morning and 1 capsule in the evening), every day. More frequent administration or a greater number of inhalations (more than 1 capsule twicedaily) is not recommended

    Clinical Results

    FDA Approval

    The FDA approval of Utibron Neohaler was based on results of the phase III EXPEDITION trial program, which included 2,654 patients with COPD and consisted of two 12-week efficacy studies (FLIGHT 1 & 2) and one 52-week safety study (FLIGHT 3). In the efficacy studies, Utibron Neohaler demonstrated superior and sustained improvements in lung function (FEV1 AUC0-12) at week 12, compared to its individual bronchodilator components (indacaterol 27.5 mcg and glycopyrrolate 15.6 mcg) as well as placebo, all dosed twice-daily. Improvements in lung function were seen compared to placebo at 5 minutes after the first dose and sustained through the 12 hour dosing interval. Utibron Neohaler also showed clinically meaningful improvements in health-related quality of life and reduced use of rescue medication compared to placebo.

    Side Effects

    Adverse effects associated with the use of Utibron Neohaler may include, but are not limited to, the following:

    • nasopharyngitis
    • hypertension

    Utibron Neohaler comes with a black box warning of the potential for long-acting beta2-adrenergic agonists (LABAs) to increase the risk of asthma-related death.

    Mechanism of Action

    Utibron Neohaler is a fixed dose combination of glycopyrronium bromide, a once-daily long-acting muscarinic antagonist, and indacaterol, a once-daily long-acting beta-2 agonist.

    Additional Information

    For additional information regarding Utibron Neohaler or the long term, maintenance treatment of airflow obstruction in patients with COPD, please visit http://www.pharma.us.novartis.com/product/pi/pdf/utibron.pdf

    Approval Date: 2015-10-01
    Date Created: 2015-11-02 02:08:50
    Company Name: Novartis
    Back to Listings

    Upcoming Events

    • 16Dec

      Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

    Featured Products

    • Regenerative-medicine-steps-to-accelerate-development-pdf

      Regenerative Medicine: Steps to Accelerate Development — PDF

    • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

      Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

    Featured Stories

    • Ich_logo

      ICH Overhauls 22-Year-Old Clinical Studies Guideline

    • Survey_chart2019

      Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

    • China-360x240

      U.S. Tops List of Trial Startups With China Making Progress in Phase 1

    • Phoneapp-360x240

      Device Apps Present Unique Risks in Trials

    New!

    2019 Site Survey Reports

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing